Chromosome abnormalities after autologous bone marrow transplantation with marrow treated by cyclophosphamide derivatives. 1985

J van den Akker, and N C Gorin, and J P Laporte, and L Douay, and M Lopez, and J L Taillemite, and A Najman, and G Duhamel

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014182 Transplantation, Autologous Transplantation of an individual's own tissue from one site to another site. Autografting,Autologous Transplantation,Autotransplantation,Autograftings,Autologous Transplantations,Autotransplantations,Transplantations, Autologous
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting

Related Publications

J van den Akker, and N C Gorin, and J P Laporte, and L Douay, and M Lopez, and J L Taillemite, and A Najman, and G Duhamel
February 1993, Cancer genetics and cytogenetics,
J van den Akker, and N C Gorin, and J P Laporte, and L Douay, and M Lopez, and J L Taillemite, and A Najman, and G Duhamel
February 1993, Critical reviews in oncology/hematology,
J van den Akker, and N C Gorin, and J P Laporte, and L Douay, and M Lopez, and J L Taillemite, and A Najman, and G Duhamel
January 1986, Haematologica,
J van den Akker, and N C Gorin, and J P Laporte, and L Douay, and M Lopez, and J L Taillemite, and A Najman, and G Duhamel
January 1989, Cancer chemotherapy and pharmacology,
J van den Akker, and N C Gorin, and J P Laporte, and L Douay, and M Lopez, and J L Taillemite, and A Najman, and G Duhamel
January 1989, Cancer investigation,
J van den Akker, and N C Gorin, and J P Laporte, and L Douay, and M Lopez, and J L Taillemite, and A Najman, and G Duhamel
May 1969, Cancer research,
J van den Akker, and N C Gorin, and J P Laporte, and L Douay, and M Lopez, and J L Taillemite, and A Najman, and G Duhamel
May 1988, Blood,
J van den Akker, and N C Gorin, and J P Laporte, and L Douay, and M Lopez, and J L Taillemite, and A Najman, and G Duhamel
January 1984, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology,
J van den Akker, and N C Gorin, and J P Laporte, and L Douay, and M Lopez, and J L Taillemite, and A Najman, and G Duhamel
October 1988, Journal of the National Cancer Institute,
J van den Akker, and N C Gorin, and J P Laporte, and L Douay, and M Lopez, and J L Taillemite, and A Najman, and G Duhamel
March 1974, British medical journal,
Copied contents to your clipboard!